Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab for Acute Graft Versus Host Disease (EQUATOR)
NCT05263999Phase 3Terminated
- Sponsor
- Equillium, Inc.
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of itolizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Equillium, Inc.. Started Apr 2022; status: terminated.
02
Drugs
itolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05263999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263999.